

# Michael A. O'Rorke, PhD, PGCHET

College of Public Health Curriculum Vitae

Department of Epidemiology

michael-ororke@uiowa.edu

(319) 384-1560

March 2026

## Educational and Professional History

### Degrees Earned

- |      |   |
|------|---|
| 2007 | BSc Physiotherapy, Faculty of Life & Health Sciences, University of Ulster, Northern Ireland  |
| 2011 | PhD in Cancer Epidemiology, School of Medicine, Dentistry & Biomedical Sciences, Queens University, Belfast, Northern Ireland<br>Mentors: Liam Murray, Mentors: Liam Murray, Marie Cantwell, Dissertation: Physical activity, nutrition and the aetiology of upper gastrointestinal tract cancers |
| 2012 | PGCHET in Post Graduate Certificate in Higher Education Teaching, School of Education, Queens University, Belfast, Northern Ireland   |

### Employment History

- |                |  |
|----------------|--|
| 2011 - 2014    | Postdoctoral Research Fellow (Pharmacoepidemiology), School of Pharmacy/Centre for Public Health, Queen's University Belfast   |
| 2014 - 2018    | Cancer Research UK Population Research Committee Postdoctoral Fellowship, Centre for Public Health, Queen's University Belfast<br>Project: Beta-adrenergic receptor expression and beta-blocker drug use: association with breast cancer survival and prognosis<br>Funding: £151,216, including salary for the fellow over 3 years |
| 2016 - 2018    | Knowledge, Transfer and Exchange (KTE) Officer, UKCRC Centre of Excellence for Public Health Northern Ireland  |
| 2019 - 2021    | Secondary appointment, Pathology, University of Iowa, Iowa City, Iowa  |
| 2018 - Present | Assistant Professor, Epidemiology, University of Iowa, Iowa City, Iowa   |

### Honors and Awards

- |      |   |
|------|---|
| 2009 | 1st Prize School of Medicine, QUB PhD Showcase Event, Queen's University Belfast, Northern Ireland, UK  |
| 2009 | Scholarship - Ireland-Northern Ireland National Cancer Institute Consortium, Principles and Practice of Cancer Prevention and Control - summer course, Washington DC. |
| 2014 | Queen's University Belfast, School of Medicine, Annual Celebration of Excellence – Best Post-Doctoral Research Fellow (Nominee), Belfast, Northern Ireland, UK        |
| 2024 | CPH Faculty Teaching Award  |

2025	The President & Provost Award for Teaching Excellence (Nominee), University of Iowa, Iowa City, IA
2011 - Present	Fellow of the Higher Education Academy (FHEA), UK
2022 - Present	Delta Omega Honorary Society in Public Health (Alpha Phi chapter), University of Iowa, Iowa City, IA

## Teaching

### Course Teaching

#### University of Iowa

Spring 2019	Cancer Epidemiology and Control, EPID:6700:0001, Credit Hours: 3, Enr: 10, Percent of Course: 5.0%
Fall 2019	Epidemiology I: Principles, EPID:4400:0001, Credit Hours: 3, Enr: 78, Percent of Course: 50.0%
Fall 2019	Introduction to Human Pathology, PATH:8133:0A05, Credit Hours: 4, Enr: 23, Percent of Course: 100.0%
Summer 2020	Epidemiology I: Principles, EPID:4400:0EXW, Credit Hours: 3, Enr: 41, Percent of Course: 100.0%
Fall 2019 - Fall 2020	PATH:8133:0A05 Introduction to Human Pathology, Credit Hours: 1
Fall 2020	Epidemiology I: Principles, EPID:4400:0001, Credit Hours: 3, Enr: 68, Percent of Course: 50.0%
Fall 2020	Epidemiology I: Principles, EPID:4400:0EXW, Credit Hours: 3, Enr: 14, Percent of Course: 50.0%
Fall 2020	Epidemiology Journal Club, EPID:5925:0002, Enr: 38
Fall 2020	Introduction to Human Pathology, PATH:8133:0A05, Credit Hours: 4, Enr: 24, Percent of Course: 100.0%
Spring 2021	Epidemiology I: Principles, EPID:4400:0EXW, Credit Hours: 3, Enr: 31, Percent of Course: 100.0%
Summer 2021	Epidemiology I: Principles, EPID:4400:0EXW, Credit Hours: 3, Enr: 20, Percent of Course: 100.0%
Fall 2021	Epidemiology I: Principles, EPID:4400:0001, Credit Hours: 3, Enr: 71, Percent of Course: 100.0%
Fall 2021	Epidemiology I: Principles, EPID:4400:0EXW, Credit Hours: 3, Enr: 11, Percent of Course: 100.0%
Spring 2022	Epidemiology I: Principles, EPID:4400:0EXW, Credit Hours: 3, Enr: 24, Percent of Course: 100.0%
Fall 2022	Epidemiology I: Principles, EPID:4400:0001, Credit Hours: 3, Enr: 67, Percent of Course: 100.0%
Fall 2022	Epidemiology I: Principles, EPID:4400:0EXW, Credit Hours: 3, Enr: 11, Percent of Course: 100.0%
Spring 2022 - Spring 2023	EPID:6400 Epidemiology II

Spring 2023	Biomarkers in Epidemiology, EPID:5560:0001, Credit Hours: 3, Enr: 22, Percent of Course: 100.0%
Fall 2023	Epidemiology I: Principles, EPID:4400:0001, Credit Hours: 3, Enr: 64, Percent of Course: 100.0%
Fall 2023	Epidemiology I: Principles, EPID:4400:0EXW, Credit Hours: 3, Enr: 11, Percent of Course: 100.0%
Fall 2023	Epidemiology Journal Club, EPID:5925:0002, Enr: 43
Spring 2024	Epidemiology I: Principles, EPID:4400:0EXW, Credit Hours: 3, Enr: 4, Percent of Course: 100.0%
Spring 2024	Epidemiology Journal Club, EPID:5925:0001, Enr: 44
Fall 2024 - Fall 2024	Epidemiology I: Principles, EPID:4400:0001, Credit Hours: 3, Enr: 70, Percent of Course: 100%
Fall 2024 - Fall 2024	Epidemiology I: Principles, EPID:4400:0EXW, Credit Hours: 3, Enr: 6, Percent of Course: 100%
Spring 2022 - Spring 2025	NURS:7404:0001 Biological Markers in Health Research
Spring 2025 - Spring 2025	Biomarkers in Epidemiology, EPID:5560:0001, Credit Hours: 3, Enr: 14, Percent of Course: 100%
Fall 2025	Epidemiology I: Principles, EPID:4400:0001, Credit Hours: 3, Enr: 62, Percent of Course: 100%
Fall 2025	Epidemiology I: Principles, EPID:4400:0EXW, Credit Hours: 3, Enr: 5, Percent of Course: 100%
Spring 2026 - Spring 2026	Epidemiology I: Principles, EPID:4400:0EXW, Credit Hours: 3, Enr: 3, Percent of Course: 100%
Spring 2021 - Present	FRRB:7001 Molecular and Cellular Biology of Cancer
Spring 2024 - Present	EPID:6600 Chronic Disease Epidemiology
Fall 2025 - Present	EPID:5500 Introduction to Clinical Epidemiology

#### Other Institutions

2014 - 2016	MSc Bioinformatics and Computational Genomics (Topic: Introduction to epidemiology), Queens University, Belfast, Credit Hours: 2 Role: Guest Lecturer; Topic: Introduction to epidemiology
2011 - 2018	MED2015 Bachelor of medicine (Tutorial - Topic: Year 2 Epidemiology), Queens University, Belfast, Credit Hours: 12 Role: Guest Lecturer; Topic: Year 2 - Epidemiology
2012 - 2018	SCM3001 BSc Hons Human Biology & Bsc Hons Food Quality, Safety & Nutrition (Topic: Hypertension), Queens University, Belfast, Credit Hours: 1 Role: Guest Lecturer; Lecture: Hypertension
2013 - 2018	MSc Public Health (Topic: Sun exposure or obesity), Queens University, Belfast, Credit Hours: 1 Role: Guest Lecturer; Topic: Sun exposure or obesity

2013 - 2018	Student Select Component, MB, BCh, BAO: Bachelor of medicine (Topic: Cancer screening in high risk populations), Queens University, Belfast, Credit Hours: 1 Role: Guest Lecturer; Topic: Cancer screening in high risk populations
2015 - 2018	MB, BCh, BAO: Bachelor of medicine (Tutorial - Topic: Year 1 Diagnostic studies), Queens University, Belfast, Credit Hours: 2 Topic: Year 1 - Diagnostic studies

## Scholarship/Professional Productivity

### Publications or creative works

#### Peer-reviewed papers and journal articles

1. **O'Rorke, M. A.**, Cantwell, M. M., Cardwell, C. R., Mulholland, H. G. & Murray, L. J. Can physical activity modulate pancreatic cancer risk? a systematic review and meta-analysis. *Int J Cancer*. 2010 126 (12) 2957-68. DOI: 10.1002/ijc.24997. PMID: 19856317.  
ISSN: 0020-7136
2. **O'Rorke, M. A.**, Cantwell, M. M., Abnet, C. C., Brockman, A. J. & Murray, L. J. Toenail trace element status and risk of Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. *Int J Cancer*. 2012 131 (8) 1882-91. DOI: 10.1002/ijc.27434. PMID: 22262413. PMCID: PMC3545279.  
ISSN: 0020-7136
3. **O'Rorke, M. A.**, Ellison, M. V., Murray, L. J., Moran, M., James, J. & Anderson, L. A. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. *Oral Oncology*. 2012 48 (12) 1191-201. DOI: 10.1016/j.oraloncology.2012.06.019. PMID: 22841677.  
ISSN: 1368-8375
4. Abdullah, F., **O'Rorke, M.**, Murray, L. & Su, T. T. Evaluation of a worksite cervical screening initiative to increase Pap smear uptake in Malaysia: a cluster randomized controlled trial. *BioMed Research International*. 2013 572126. DOI: 10.1155/2013/572126. PMID: 24073411. PMCID: PMC3773923.  
ISSN: 2314-6133
5. Anderson, L., **O'Rorke, M.**, Jamison, J., Wilson, R. & Gavin, A. Prevalence of human papillomavirus in women attending cervical screening in the UK and Ireland: new data from northern Ireland and a systematic review and meta-analysis. *Journal of Medical Virology*. 2013 85 (2) 295-308. DOI: 10.1002/jmv.23459. PMID: 23161367.  
ISSN: 0146-6615
6. **O'Rorke, M. A.**, Black, C., Murray, L. J., Cardwell, C. R., Gavin, A. T. & Cantwell, M. M. Do perinatal and early life exposures influence the risk of malignant melanoma? A Northern Ireland birth cohort analysis. *European Journal of Cancer*. 2013 49 (5) 1109-16. DOI: 10.1016/j.ejca.2012.10.017. PMID: 23146960.  
ISSN: 0959-8049
7. Bannon, F. J., **O'Rorke, M. A.**, Murray, L. J., Hughes, C. M., Gavin, A. T., Fleming, S. J. & Cardwell, C. R. Non-steroidal anti-inflammatory drug use and brain tumour risk: a case-control study within the Clinical Practice Research Datalink. *Cancer Causes & Control*. 2013 24 (11) 2027-34. DOI: 10.1007/s10552-013-0279-9. PMID: 23990380.  
ISSN: 0957-5243
8. Wilson, J. C., **O'Rorke, M. A.**, Cooper, J. A., Murray, L. J., Hughes, C. M., Gormley, G. J. & Anderson, L. A. Non-steroidal anti-inflammatory drug use and cervical cancer risk: a case-control study using the Clinical Practice Research Datalink. *Cancer Epidemiology*. 2013 37 (6) 897-904. DOI: 10.1016/j.canep.2013.08.010. PMID: 24042024.

ISSN: 1877-7821

9. McShane, C. M., Murray, L. J., Landgren, O., **O'Rorke, M. A.**, Korde, N., Kunzmann, A. T., Ismail, M. R. & Anderson, L. A. Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. *Cancer Epidemiology Biomarkers Prevention*. 2014 23 (2) 332-42. DOI: 10.1158/1055-9965.EPI-13-0695. PMID: 24451437.  
ISSN: 1055-9965
10. Titmarsh, G. J., Duncombe, A. S., McMullin, M. F., **O'Rorke, M.**, Mesa, R., De Vocht, F., Horan, S., Fritschi, L., Clarke, M. & Anderson, L. A. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. *American Journal of Hematology*. 2014 89 (6) 581-7. DOI: 10.1002/ajh.23690.  
PMID: 24971434.  
ISSN: 0361-8609
11. **O'Rorke, M. A.**, Murray, L. J., Hughes, C. M., Cantwell, M. M. & Cardwell, C. R. The effect of warfarin therapy on breast, colorectal, lung, and prostate cancer survival: a population-based cohort study using the Clinical Practice Research Datalink. *Cancer Causes & Control*. 2015 26 (3) 355-66. DOI: 10.1007/s10552-014-0511-2. PMID: 25534917.  
ISSN: 0957-5243
12. **O'Rorke, M. A.**, Murray, L. J., Brand, J. S. & Bhoo-Pathy, N. The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients. *Cancer treatment reviews*. 2016 47 12-21. DOI: 10.1016/j.ctrv.2016.05.001. PMID: 27214603.  
ISSN: 0305-7372
13. Anderson, L. A., **O'Rorke, M. A.**, Wilson, R., Jamison, J. & Gavin, A. T. HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix: A population-based study from Northern Ireland. *Journal of medical virology*. 2016 88 (7) 1262-70. DOI: 10.1002/jmv.24447. PMID: 26680281.  
ISSN: 0146-6615
14. Cardwell, C. R., Pottegård, A., Vaes, E., Garmo, H., Murray, L. J., Brown, C., Vissers, P. A., **O'Rorke, M.**, Visvanathan, K., Cronin-Fenton, D., De Schutter, H., Lambe, M., Powe, D. G., van Herk-Sukel, M. P., Gavin, A., Friis, S., Sharp, L. & Bennett, K. Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts. *Breast cancer research*. 2016 18 (1) 119. DOI: 10.1186/s13058-016-0782-5. PMID: 27906047. PMCID: PMC5133766.  
ISSN: 1465-5411
15. Gomez-Rubio, P., Zock, J. P., Rava, M., Marquez, M., Sharp, L., Hidalgo, M., Carrato, A., Ilzarbe, L., Michalski, C., Molero, X., Farré, A., Perea, J., Greenhalf, W., **O'Rorke, M.**, Tardón, A., Gress, T., Barberà, V., Crnogorac-Jurcevic, T., Domínguez-Muñoz, E., Muñoz-Bellvís, L., Alvarez-Urturi, C., Balcells, J., Barneo, L., Costello, E., Guillén-Ponce, C., Kleeff, J., Kong, B., Lawlor, R., Löhr, M., Mora, J., Murray, L., O'Driscoll, D., Peláez, P., Poves, I., Scarpa, A., Real, F. X. & Malats, N. Reduced risk of pancreatic cancer associated with asthma and nasal allergies. *Gut*. 2017 66 (2) 314-322. DOI: 10.1136/gutjnl-2015-310442. PMID: 26628509.  
ISSN: 0017-5749
16. Gomez-Rubio, P., Rosato, V., Márquez, M., Bosetti, C., Molina-Montes, E., Rava, M., Piñero, J., Michalski, C. W., Farré, A., Molero, X., Löhr, M., Ilzarbe, L., Perea, J., Greenhalf, W., **O'Rorke, M.**, Tardón, A., Gress, T., Barberà, V. M., Crnogorac-Jurcevic, T., Muñoz-Bellvís, L., Domínguez-Muñoz, E., Gutiérrez-Sacristán, A., Balsells, J., Costello, E., Guillén-Ponce, C., Huang, J., Iglesias, M., Kleeff, J., Kong, B., Mora, J., Murray, L., O'Driscoll, D., Peláez, P., Poves, I., Lawlor, R. T., Carrato, A., Hidalgo, M., Scarpa, A., Sharp, L., Furlong, L. I., Real, F. X., La Vecchia, C. & Malats, N. (2017). A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. *Annals Oncol*. 2017 28 (7) 1618-1624. DOI: 10.1093/annonc/mdx167. PMID: 28383714.  
ISSN: 0923-7534

17. Van der Graaf, P., Francis, O., Doe, E., Barrett, E., **O'Rorke, M.** & Docherty, G. Structural approaches to knowledge exchange: comparing practices across five centres of excellence in public health. *Journal of Public Health*. 2018 40 (suppl\_1) i31-i38. DOI: 10.1093/pubmed/fox150. PMID: 29538725. ISSN: 1741-3842
18. Molina-Montes, E., Gomez-Rubio, P., Márquez, M., Rava, M., Löhr, M., Michalski, C. W., Molero, X., Farré, A., Perea, J., Greenhalf, W., Ilzarbe, L., **O'Rorke, M.**, Tardón, A., Gress, T., Barberà, V. M., Crnogorac-Jurcevic, T., Domínguez-Muñoz, E., Muñoz-Bellvís, L., Balsells, J., Costello, E., Huang, J., Iglesias, M., Kleeff, J., Kong, B., Mora, J., Murray, L., O'Driscoll, D., Poves, I., Scarpa, A., Ye, W., Hidalgo, M., Sharp, L., Carrato, A., Real, F. X. & Malats, N. (2018). Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. *Int J Epidemiology*. 2018 47 (2) 473-483. DOI: 10.1093/ije/dyx269. PMID: 29329392. ISSN: 0300-5771
19. Spence, A. D., Busby, J., Murchie, P., Kunzmann, A. T., McMenamin, Ú. C., Coleman, H. G., Johnston, B. T., **O'Rorke, M. A.**, Murray, L. J., Iversen, L., Lee, A. J. & Cardwell, C. R. Medications that relax the lower oesophageal sphincter and risk of oesophageal cancer: An analysis of two independent population-based databases. *Int J Cancer*. 2018 143 (1) 22-31. DOI: 10.1002/ijc.31293. PMID: 29396851. ISSN: 0020-7136
20. Humphries, M. P., Hynes, S., Bingham, V., Cougot, D., James, J., Patel-Socha, F., Parkes, E. E., Blayney, J. K., **O'Rorke, M. A.**, Irwin, G. W., McArt, D. G., Kennedy, R. D., Mullan, P. B., McQuaid, S., Salto-Tellez, M. & Buckley, N. E. Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. *Journal of oncology* 2018 2937012. DOI: 10.1155/2018/2937012. PMID: 30651729. PMCID: PMC6311859. ISSN: 1687-8450
21. Gomez-Rubio, P., Piñero, J., Molina-Montes, E., Gutiérrez-Sacristán, A., Marquez, M., Rava, M., Michalski, C. W., Farré, A., Molero, X., Löhr, M., Perea, J., Greenhalf, W., **O'Rorke, M.**, Tardón, A., Gress, T., Barberà, V. M., Crnogorac-Jurcevic, T., Muñoz-Bellvís, L., Domínguez-Muñoz, E., Balsells, J., Costello, E., Yu, J., Iglesias, M., Ilzarbe, L., Kleeff, J., Kong, B., Mora, J., Murray, L., O'Driscoll, D., Poves, I., Lawlor, R. T., Ye, W., Hidalgo, M., Scarpa, A., Sharp, L., Carrato, A., Real, F. X., Furlong, L. I. & Malats, N. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. *Int J Cancer* 2019 144 (7) 1540-1549. DOI: 10.1002/ijc.31866. PMID: 30229903. ISSN: 0020-7136
22. Kong, Y. C., Bhoo-Pathy, N., **O'Rorke, M.**, Subramaniam, S., Bhoo-Pathy, N. T., See, M. H., Jamaris, S., Teoh, K. H., Bustam, A. Z., Looi, L. M., Taib, N. A. & Yip, C. H. The association between methods of biopsy and survival following breast cancer: A hospital registry based cohort study. *Medicine*. 2020 99 (6) e19093. DOI: 10.1097/MD.000000000019093. PMID: 32028433. PMCID: PMC7015568. ISSN: 0025-7974
23. Elshahat, S., **O'Rorke, M.** & Adlakha, D. Built environment correlates of physical activity in low- and middle-income countries: A systematic review. *PloS one*. 2020 15 (3) e0230454. DOI: 10.1371/journal.pone.0230454. PMID: 32182278. PMCID: PMC7077823.
24. Molina-Montes, E., Van Hoogstraten, L., Gomez-Rubio, P., Löhr, M., Sharp, L., Molero, X., Márquez, M., Michalski, C. W., Farré, A., Perea, J., **O'Rorke, M.**, Greenhalf, W., Ilzarbe, L., Tardon, A., Gress, T. M., Barberà, V. M., Crnogorac-Jurcevic, T., Muñoz-Bellvis, L., Domínguez-Muñoz, E., Balsells, J., Costello, E., Iglesias, M., Kleeff, J., Kong, B., Mora, J., O'Driscoll, D., Poves, I., Scarpa, A., Yu, J., Ye, W., Hidalgo, M., Carrato, A., Lawlor, R., Real, F. X. & Malats, N. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. *Cancer Epi Biomarker Prev*. 2020. 29 (5) 1009-1018. DOI: 10.1158/1055-9965.EPI-19-1027. PMID: 32051190.
25. Molina-Montes, E., Coscia, C., Gómez-Rubio, P., Fernández, A., Boenink, R., Rava, M., Márquez, M., Molero, X., Löhr, M., Sharp, L., Michalski, C. W., Farré, A., Perea, J., **O'Rorke, M.**, Greenhalf, W., Iglesias, M., Tardón, A., Gress, T. M., Barberà, V. M., Crnogorac-Jurcevic, T., Muñoz-Bellvís, L., Dominguez-

- Muñoz, J. E., Renz, H., Balcells, J., Costello, E., Ilzarbe, L., Kleeff, J., Kong, B., Mora, J., O'Driscoll, D., Poves, I., Scarpa, A., Yu, J., Hidalgo, M., Lawlor, R. T., Ye, W., Carrato, A., Real, F. X. & Malats, N. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. *Gut*. 2021 70 (2) 319-329. DOI: 10.1136/gutjnl-2019-319990. PMID: 32409590. ISSN: 0017-5749
26. Weeks, K., Lynch, C. F., West, M., Carnahan, R., **O'Rorke, M.**, Oleson, J., McDonald, M., Stewart, S. L. & Charlton, M. Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients. *Gynecologic oncology*. 2021. 160 (2) 477-484. DOI: 10.1016/j.ygyno.2020.11.006. PMID: 33218682. PMCID: PMC7869694. ISSN: 0090-8258
  27. de López Maturana, E., Rodríguez, J. A., Alonso, L., Lao, O., Molina-Montes, E., Martín-Antoniano, I. A., Gómez-Rubio, P., Lawlor, R., Carrato, A., Hidalgo, M., Iglesias, M., Molero, X., Löhr, M., Michalski, C., Perea, J., **O'Rorke, M.**, Barberà, V. M., Tardón, A., Farré, A., Muñoz-Bellvís, L., Crnogorac-Jurcevic, T., Domínguez-Muñoz, E., Gress, T., Greenhalf, W., Sharp, L., Arnes, L., Cecchini, L., Balsells, J., Costello, E., Ilzarbe, L., Kleeff, J., Kong, B., Márquez, M., Mora, J., O'Driscoll, D., Scarpa, A., Ye, W., Yu, J., García-Closas, M., Kogevinas, M., Rothman, N., Silverman, D. T., Albanes, D., Arslan, A. A., Beane-Freeman, L., Bracci, P. M., Brennan, P., Bueno-de-Mesquita, B., Buring, J., Canzian, F., Du, M., Gallinger, S., Gaziano, J. M., Goodman, P. J., Gunter, M., LeMarchand, L., Li, D., Neale, R. E., Peters, U., Petersen, G. M., Risch, H. A., Sánchez, M. J., Shu, X. O., Thornquist, M. D., Visvanathan, K., Zheng, W., Chanock, S. J., Easton, D., Wolpin, B. M., Stolzenberg-Solomon, R. Z., Klein, A. P., Amundadottir, L. T., Marti-Renom, M. A., Real, F. X. & Malats, N. (2021). A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. *Genome medicine* 13 (1) 15. DOI: 10.1186/s13073-020-00816-4. PMID: 33517887. PMCID: PMC7849104.
  28. Herbach, E. L., Weeks, K. S., **O'Rorke, M.**, Novak, N. L. & Schweizer, M. L. Disparities in breast cancer stage at diagnosis between immigrant and native-born women: A meta-analysis. *Annals of epidemiology*. 2021 54 64-72.e7. DOI: 10.1016/j.annepidem.2020.09.005. PMID: 32950654. ISSN: 1047-2797
  29. Weeks, K. S., Lynch, C. F., West, M. M., Carnahan, R. M., **O'Rorke, M. A.**, Oleson, J. J., McDonald, M. E. & Charlton, M. E. Impact of Surgeon Type and Rurality on Treatment and Survival of Ovarian Cancer Patients. *American journal of clinical oncology*. 2021 44 (10) 544-551. DOI: 10.1097/COC.0000000000000860. PMID: 34342289. PMCID: PMC8801132. ISSN: 0277-3732
  30. Rosato, V., Gómez-Rubio, P., Molina-Montes, E., Márquez, M., Löhr, M., **O'Rorke, M.**, Michalski, C. W., Molero, X., Farré, A., Perea, J., Kleeff, J., Crnogorac-Jurcevic, T., Greenhalf, W., Ilzarbe, L., Tardón, A., Gress, T., Barberá, V. M., Domínguez-Muñoz, E., Muñoz-Bellvís, L., Balsells, J., Costello, E., Iglesias, M., Kong, B., Mora, J., O'Driscoll, D., Poves, I., Scarpa, A., Ye, W., Hidalgo, M., Sharp, L., Carrato, A., Real, F. X., La Vecchia, C. & Malats, N. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. *European journal of cancer prevention*. 2021 30 (6) 423-430. DOI: 10.1097/CEJ.0000000000000588. PMID: 34545020. ISSN: 0959-8278
  31. Weeks, K. S., Lynch, C. F., West, M., Carnahan, R., **O'Rorke, M.**, Oleson, J., McDonald, M., Stewart, S. L. & Charlton, M. Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients. *Gynecologic oncology*. 2022 164 (1) 3-11. DOI: 10.1016/j.ygyno.2021.11.001. PMID: 34776243. ISSN: 0090-8258
  32. Akinoso-Imran, A. Q., **O'Rorke, M.**, Kee, F., Jordao, H., Walls, G. & Bannon, F. J. (2022). Surgical under-treatment of older adult patients with cancer: A systematic review and meta-analysis. *Journal of geriatric oncology* 13 (4) 398-409. DOI: 10.1016/j.jgo.2021.11.004. PMID: 34776385.

33. Ece Kartal, Thomas S B Schmidt, Esther Molina-Montes, Sandra Rodríguez-Perales, Jakob Wirbel, Oleksandr M Maistrenko, Wasiu A Akanni, Bilal Alashkar Alhamwe, Renato J Alves, Alfredo Carrato, Hans-Peter Erasmus, Lidia Estudillo, Fabian Finkelmeier, Anthony Fullam, Anna M Glazek, Paulina Gómez-Rubio, Rajna Hercog, Ferris Jung, Stefanie Kandels, Stephan Kersting, Melanie Langheinrich, Mirari Márquez, Xavier Molero, Askarbak Orakov, Thea Van Rossum, Raul Torres-Ruiz, Anja Telzerow, Konrad Zych; MAGIC Study investigators; **PanGenEU Study investigators**; Vladimir Benes, Georg Zeller, Jonel Trebicka, Francisco X Real, Nuria Malats, Peer Bork. A faecal microbiota signature with high specificity for pancreatic cancer. *Gut*. 2022 71 (7) 1359-1372. DOI: 10.1136/gutjnl-2021-324755. PMID: 35260444. PMCID: PMC9185815.  
ISSN: 0017-5749; PanGenEU Study investigators - The data and validation data from this study includes data collected from the PanGEN-EU study - including my PanCAM Ireland study.
34. Herbach, E., **O'Rorke, M. A.**, Carnahan, R. M., McDowell, B. D., Allen, B., Grumbach, I., London, B., Smith, B. J., Spitz, D. R., Seaman, A. & Chrischilles, E. A. Cardiac Adverse Events Associated With Chemo-Radiation Versus Chemotherapy for Resectable Stage III Non-Small-Cell Lung Cancer: A Surveillance, Epidemiology and End Results-Medicare Study. *Journal of the American Heart Association*. 2022 11 (23) e027288. DOI: 10.1161/JAHA.122.027288. PMID: 36453633. PMCID: PMC9851429.
35. McDowell BD, **O'Rorke MA**, Schroeder MC, Chrischilles EA, Spinka CM, Waitman LR, Anuforo K, Araya A, Bah H, Barlocker J, Chandaka S, Cowell LG, Geary CR, Gupta S, Horne BD, Knosp BM, Lai AM, Mandhadi V, Mohammad Mosa AS, Reeder P, Ryu G, Shukwit B, Smith C, Stoddard AJ, Syed M, Syed S, Taylor BW, VanWormer JJ. Implementing Cancer Registry Data With the PCORnet Common Data Model: The Greater Plains Collaborative Experience. <https://pubmed.ncbi.nlm.nih.gov/39689273/> *J CO Clin Cancer Inform*. 2024 Dec;8:e2400196. doi: 10.1200/CCI-24-00196. Epub 2024 Dec 17. PMID: 39689273 PMCID: PMC11658786
36. Alade A, Peter T, Busch T, Awotoye W, Anand D, Abimbola O, Aladenika E, Olujitan M, Rysavy O, Nguyen PF, Naicker T, Mossey PA, Gowans LJJ, Eshete MA, Adeyemo WL, Zeng E, Van Otterloo E, **O'Rorke M**, Adeyemo A, Murray JC, Lachke SA, Romitti PA, Butali A. Shared genetic risk between major orofacial cleft phenotypes in an African population. <https://pubmed.ncbi.nlm.nih.gov/38634654/> *Genet Epidemiol*. 2024 Sep;48(6):258-269. doi: 10.1002/gepi.22564. Epub 2024 Apr 18. PMID: 38634654
37. Alade A, Mossey P, Awotoye W, Busch T, Oladayo AM, Aladenika E, Olujitan M, Wentworth E, Anand D, Naicker T, Gowans LJJ, Eshete MA, Adeyemo WL, Zeng E, Van Otterloo E, **O'Rorke M**, Adeyemo A, Murray JC, Cotney J, Lachke SA, Romitti P, Butali A. Rare variants analyses suggest novel cleft genes in the African population. <https://pubmed.ncbi.nlm.nih.gov/38902479/> *Sci Rep*. 2024 Jun 20;14(1):14279. doi: 10.1038/s41598-024-65151-9. PMID: 38902479, PMCID: PMC11189897
38. Tao Xu, Joseph S Dillon, Mary A Maluccio, Dawn E Quelle, Sarah H Nash, Hyunkeun Cho, Kristen E Limbach, Nicholas J Skill, Yvette Bren-Mattison, **Michael A O'Rorke**. Peptide Receptor Radionuclide Therapy and clinical associations with renal and hematological toxicities and survival in patients with neuroendocrine tumors: an analysis from two U.S. medical centers. *J Cancer Res Clin Oncol*. 2024 Nov 2;150(11):485. PMID: 39488644, PMCID: PMC11531437
39. **Michael O'Rorke**, Elizabeth Chrischilles; NET-PRO Study Investigators. 2024. Making progress against rare cancers: A case study on neuroendocrine tumors. *Cancer*. DOI: 10.1002/cncr.35184. PMID: 38244195, PMCID: PMC11177581  
ISSN: 0008-543X
40. **Michael A. O'Rorke**, PhD, Bradley D. McDowell, PhD, Tao Xu, PhD, Brian M. Gryzlak, MSW, MA, Rhonda R. DeCook, PhD, Nicholas J. Rudzianski, BS, Kimberly C. Serrano, BA, Abigayle M. Wehrheim, BS, Udhayvir S. Grewal, MD, Chandrikha Chandrasekharan, MBBS, Joseph S. Dillon, MB BCh, Thorvardur R. Halfdanarson, MD, Michael J. Schnell, MS, Carrie L. Witter, BS, T. Clark Gamblin, MD, Syed Kazmi, MD, Lindsay G. Cowell, PhD, Tobias Else, MD, Heloisa P. Soares, MD, PhD, Vineeth Sukrithan, MD, Sravani Chandaka, PhD, Hanna K. Sanoff, MD, Fiona C. He, MD, David A. Geller, MD, Robert A. Ramirez, DO, Mei

- Liu, PhD, William Lancaster, MD, Josh A. Mailman, MBA, Heather Moran, MEd, Maryann Wahmann, Elyse Gellerman, MHS, Elizabeth A. Chrischilles, PhD, on behalf of the NET-PRO Study Investigators. Assessing Patient Characteristics in Neuroendocrine Tumor Research: A Comparison of the NET-PRO Study to SEER Population-Based Data. *Medical Care*. Submitted
41. **Michael A. O'Rorke**, PhD, Brian M. Gryzlak, MSW, MA, Tao Xu, PhD, Bradley D. McDowell, PhD, Rhonda R. DeCook, PhD, , Nicholas J. Rudzianski, BS, Kimberly C. Serrano, BA, Abigayle M. Wehrheim, BS, Udhayvir S. Grewal, MD, Chandrikha Chandrasekharan, MBBS, Joseph S. Dillon, MB BCh, Thorvardur R. Halfdanarson, MD, Michael J. Schnell, MS, Carrie L. Witter, BS, T. Clark Gamblin, MD, Syed Kazmi, MD, Lindsay G. Cowell, PhD, Tobias Else, MD, Heloisa P. Soares, MD, PhD, Vineeth Sukrithan, MD, Sravani Chandaka, PhD, Hanna K. Sanoff, MD, Fiona C. He, MD, David A. Geller, MD, Robert A. Ramirez, DO, Mei Liu, PhD, William Lancaster, MD, Josh A. Mailman, MBA, Heather Moran, MEd, Maryann Wahmann, Elyse Gellerman, MHS, Elizabeth A. Chrischilles, PhD, on behalf of the NET-PRO Study Investigators. Using a Participation Monitoring Database to Enhance Recruitment in a Rare Cancer Population. *J Clinical Translational Science*. Submitted
  42. J He, S Sabroso-Lasa, C Coscia, E López de Maturana, L Alonso, R Lawlor, A Carrato, R Alvarez-Gallego, M Iglesias, X Molero, CW Michalski, J Perea, MJ Löhr, **M O'Rorke**, VM Barberà, A Tardón, A Farré, T Crnogorac-Jurcevic, E Domínguez-Muñoz, T Gress, W Greenhalf, L Sharp, E Castello, J Kleeff, B Kong, J Mora, D O'Driscoll, A Scarpa, W Ye, FX Real, N Malats, on behalf of the PanGenEU Investigators. A Comprehensive Assessment of the Causal Relationship Between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. *Int J Epidemiology* 2025. In-Preparation
  43. Nannan Xue, Sergio Sabroso-Lasa, Xavier Merino, Maria Munzo-Beltran, Megan Schuurmans, Maria Olano, Lidia Estudillo, Maria Jesús Ledesma-Carbayo, Junqi Liu, Ruitai Fan, John J Hermans, Casper van Eijck, Nuria Malats; **PanGenEU Centres and Investigators**. A fusion-based deep-learning algorithm predicts PDAC metastasis based on primary tumour CT images: a multinational study. *Gut* 2025 Jun 19:gutjnl-2024-334237. doi: 10.1136/gutjnl-2024-334237. Online ahead of print. PMID: 40537254
  44. **Michael A O'Rorke**, Isaac R Werner, Bradley D McDowell, Elizabeth A Chrischilles. Misclassification Matters: A Case for Utilization of Histologic Coding in UK Biobank Analyses. *Cancer Epidemiol Biomarkers Prev*. 2025 Jul 1;34(7):1055-1058. doi: 10.1158/1055-9965.EPI-25-0286. PMID: 40589280
  45. Vanessa E Slater, Ryan M Carnahan, Christopher S Strouse, **Michael A O'Rorke**, Brian J Smith, Elizabeth A Chrischilles. Changes in first-line treatment patterns according to frailty in chronic lymphocytic leukemia/small lymphocytic lymphoma. *Leuk Lymphoma* 2025 Jun 26:1-12. doi: 10.1080/10428194.2025.2522373. Online ahead of print. PMID: 40569700, PMCID: PMC12259026
  46. Udhayvir Singh Grewal, Rishi Patel, Jason Semprini, **Michael O'Rorke**, Joseph S Dillon, Chandrikha Chandrasekharan. Characteristics and outcomes of patients with early-onset versus average-onset small bowel neuroendocrine tumors. 2025 *Journal of Clinical Oncology* 43 (4\_suppl), 670-670
  47. Tao Xu, Joseph S Dillon, Dawn E Quelle, Sarah H Nash, Hyunkeun Cho, Michael A O'Rorke. Risk Factors Associated with Gastroenteropancreatic and Lung Neuroendocrine Tumors: A Nested Case-Control Study from The All of Us Research Program. *Cancer Epidemiol Biomarkers Prev*. 2025 Aug 1;34(8):1395-1404. doi: 10.1158/1055-9965.EPI-25-0155. PMID: 40402080, PMCID: PMC12314517
  48. **Michael A. O'Rorke**, Tao Xu, Rhonda R. DeCook, Bradley D. McDowell, Brian M. Gryzlak, Nicholas J. Rudzianski, Kimberly C. Serrano, Abigayle M. Wehrheim, Udhayvir S. Grewal, Chandrikha Chandrasekharan, Joseph S. Dillon, Thorvardur R. Halfdanarson, T. Clark Gamblin, Lindsay G. Cowell, Tobias Else, Heloisa P. Soares, Vineeth Sukrithan, Sravani Chandaka, Hanna K. Sanoff, Fiona C. He, David A Geller, Robert A. Ramirez, Mei Liu, William Lancaster, Josh A. Mailman, Heather Moran, Maryann Wahmann, Elyse Gellerman, Elizabeth A. Chrischilles, on behalf of the NET-PRO Study Investigators. Quality of Life and Care Experiences in a U.S. Multi-Institutional Neuroendocrine Tumor Cohort. *JNCI*. Submitted/Under Review
  49. Juan Pablo Hourcade, **Michael O'Rorke**, Elizabeth Chrischilles, Nicholas J Rudzianski, Brian Gryzlak, Kerry Peterman, Chris Ortman, Sam Wolstencroft, Margaret Bean, Elyse Gellerman, Josh A Mailman, Maryann Wahmann. Personal Health Record Software for Neuroendocrine Tumors: Patient-Centered

Design Approach. *JMIR Human Factors*. 2025 Jun 3;12:e68788. doi: 10.2196/68788. PMID: 40460293, PMCID: PMC12151452.

50. A Langtry, R Rabadan, L Alonso, C van Eijck, T Macarulla, R Lawlor, A Carrato, R Alvarez, M Iglesias, X Molero, M Lörh, CW Michalski, J Perea, **M O'Rorke**, VM Barberà, A Tardón, A Farré, L Muñoz-Bellvís, T Crnogorac-Jurcevic, E Domínguez-Muñoz, T Gress, W Greenhalf, L Sharp, S Sabroso, I Filip, G Strijk, F Castet, LI Cecchini, J Balsells, E Costello, J Kleeff, B Kong, J Mora, DO'Driscoll, A Scarpa, W Ye, FX Real, N Malats, E López de Maturana, on behalf of the PanGenEU Investigators. HLA-A\*02:01 allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of the HLA variation in PDAC. *The Lancet Oncology*. Submitted/Under Review
51. Xu, T. Serrano K, **O'Rorke, M.** Delta-like Ligand 3 as a Prognostic Biomarker and Therapeutic Target in Pulmonary Neuroendocrine Neoplasms: A Systematic Review and Meta-analysis. 2025. *Frontiers in Oncol.* Submitted/Under Review
52. He, J., Alashkar Alhamwe, B., Sabroso, S., Carrato, A., Hidalgo, M., Molero, X., Iglesias, M., Perea, J., Farré, A., Tardón, A., Dominguez-Muñoz, E., Barberà, V., Muñoz-Bellvís, L., Löhr, M., Greenhalf, W., **O'Rorke, M.**, Gress, T., Crnogorac-Jurcevic, T., Gayà, A., Kleeff, J., Lawlor, R., Real, F., Renz, H. & Malats, N, PanGenEU Study Investigators. Low type-2 Immune Effectors Modulate Atopic Diseases' Protective Role in Pancreatic Cancer Risk. *Int J Cancer*. 2025 Aug 1;157(3):468-479. doi: 10.1002/ijc.35397. PMID: 40098454
53. Langtry, A., Rabadan, R., Alonso, L., Filip, I., Sabroso, S., Lawlor, R., Carrato, A., Hidalgo, M., Iglesias, M., Molero, X., Lörh, M., Michalski, C., Perea, J., **O'Rorke, M.**, Barberà, V., Tardón, A., Farré, A., Muñoz-Bellvís, L., Crnogorac-Jurcevic, T., Domínguez-Muñoz, E., Gress, T., Greenhalf, W., Sharp, L., Real, F., López de Maturana, E. & Malats, N. Deciphering the Role of Complement System Genes in Pancreatic Cancer Susceptibility and Prognosis. *Nat Commun*. 2025 Nov 28;16(1):10769. doi: 10.1038/s41467-025-65811-y. PMID: 41315260

## Books

1. Bradley, M. C., **O'Rorke, M. A.**, Cooper, J. A., Friss, S. & Habel, L. A. Pharmaceutical drugs other than hormones. In Thun, M., Schottenfeld, D., Haiman, C., Cerhan, J. & Linet, M. (Eds.) *Cancer Epidemiology and Prevention*. 2017 (Fourth ed), pp. 411-432. Oxford University Press. ISBN: 9780190238667; Co-authored chapter 23

## Abstracts

1. Paulina Gomez-Rubio, Aldo Scarpa, Linda Sharp, Manuel Hidalgo, Alfredo Carrato, Lucas Ilzarbe, Christoph Michalski, Xavier Molero, Antoni Farré, José Perea, William Greenhalf, **Michael O'Rorke**, Adonina Tardón, Thomas Gress, Víctor Barberà, Tatjana Crnogorac-Jurcevic, Enrique Domínguez-Muñoz, Luís Muñoz-Bellvís, Matthias Löhr, Francisco X Real, Núria Malats. Patterns of comorbidity and multimorbidity in pancreatic cancer patients. *Pancreatology*. 2015 15 (3):S125
2. **MA O'Rorke**, LJ Murray, N Bhoo Pathy. Overall survival in triple-negative breast cancers-Prognostic influence of type of surgery and adjuvant radiotherapy: A systematic review and meta-analysis. *Cancer Research*. 2016 76 (4\_Suppl): P3-12-10-P3-12-10
3. Miguel Santibañez, Liam J Murray, Lesley Anderson, Juan Alguacil, Sanni Uuksulainen, **Michael O'Rorke**, Linda Sharp, Timo Kauppinen, FINBAR study group. PO47 Occupational and Environmental Medicine. 2016 73 (Suppl 1): A136-A137.
4. Kristin S Weeks, Charles F Lynch, Michele West, Ryan Carnahan, **Michael O'Rorke**, Jacob Oleson, Megan McDonald, Sherri L Stewart, Ovarian Cancer Treatment Study Group, Mary Charlton. Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients. *Cancer Epi Biomarker Prev*. 2020. 29 (12\_Supplement): PO-229-PO-229
5. Alberto Langtry, Raul Rabadan, Lola Alonso, Rita Lawlor, Alfredo Carrato, María Hidalgo, Mar Iglesias, Xavier Molero, Matthias Löhr, Christoph Michalski, José Perea, **Michael O'Rorke**, Victor Manuel Barberá, Adonina Tardón, Antoni Farré, Luis Muñoz-Bellvis, Tatjana Crnogorac-Jurcevic, Enrique

- Domínguez-Muñoz, Thomas Gress, William Greenhalf, Linda Sharp, Ioan Filip, Sergio Sabroso, Joaquim Balsells, Eithne Costello, Lucas Ilzarbe, Jürg Kleeff, B Kong, Josefina Mora, Damian O'Driscoll, Aldo Scarpa, Weimin Ye, J Yu, Francisco X Real, Núria Malats, Evangelina López de Maturana. Complement system genetic variability shapes pancreatic cancer risk. *Pancreatology*. 2023 23:e28 - e29. doi:10.1016/j.pan.2023.06.474
6. Jiangchuan He, Bilal Alashkar Alhamwe, Sergio Sabroso, Alfredo Carrato, Manuel Hidalgo, Xavier Molero Richard, Mar Iglesias Coma, José Perea, Antoni Farré, Adonina Tardón, Enrique Domínguez-Muñoz, Victor Barberà, Luís Muñoz-Bellvís, Matthias Löhr, William Greenhalf, **Michael O'Rorke**, Thomas Gress, Tatjana Crnogorac-Jurcevic, Jörg Kleeff, Rita Lawlor, Francisco X Real, Harald Renz, Núria Malats. The protective effect of atopic diseases against pancreatic cancer is not driven by Th2-biomarkers. *Pancreatology* 2023. 23: e143 - e144. doi:10.1016/j.pan.2023.06.768
  7. Madison M Wahlen, Vignesh T Packiam, Sarah H Nash, Ryan M Carnahan, Knute D Carter, **Michael A O'Rorke**, Michael O'Donnell, Michael Halpern. The impact of BCG shortage on disease recurrence for patients with non-muscle invasive bladder cancer: a SEER patterns of care analysis. <https://www.sciencedirect.com/science/article/pii/S1078143924008974> *Urologic Oncology: Seminars and Original Investigations* 43 (3), 46
  8. Udhayvir S Grewal, Jamie Doggett, Tao Xu, Mats van Rooij, Matthew Gao, Lisa Yen, Josh Mailman, Po H Ear, Chandrikha Chandrasekharan, Seth J Concors, Julie Hallet, Andrew M Bellizzi, Emil Lou, **Michael A O'Rorke**, Daniel M Halperin. Online Patient and Caregiver Conversations focused on Neuroendocrine Neoplasms: A Global Thematic Analysis. *ASCO GI Symposium 2026*.
  9. Udhayvir S Grewal, Brooke Rhead, Kayla Layng, Katie Navo, Matina Fragkogianni, Vanessa Nepomuceno, Matthew Gao, Tao Xu, **Michael A O'Rorke**, Mark E Burkard, Seth J Concors, Jess E Maxwell, Joseph S Dillon, Dawn E Quelle, Po Hien Ear, Arvind N Dasari, Andrew Bellizzi, James R Howe, Daniel M Halperin, Chandrikha Chandrasekharan. Molecular and Immune Landscape of Early-Onset versus Average-Onset Well-Differentiated Enteropancreatic Neuroendocrine Tumors. *ASCO GI Symposium 2026*.

#### Non-peer-reviewed journal articles

1. **O'Rorke MA**, Zhu L, Ternes S, Selk F, Kondratick C, Snow A, Goffredo P, Hassan I. Chemotherapy or no chemotherapy? A population-based study of mutational profiling and colorectal cancer-specific survival in Iowa.
2. Werner I, Xu T, Serrano K, **O'Rorke M**. Proteomic Markers and Pancreatic Cancer Risk: a systematic review and meta-analysis
3. **O'Rorke MA**, Ternes S, Serrano K, Bashir A, Belizzi A, Rajan A. Prognostic Role of PD-L1 and Other Immune-Related Biomarkers in HER2-Positive Breast Cancer
4. **O'Rorke MA**, Xu T, Werner I, Serrano K, Grewal US MD, Strosberg JR MD, Dillion JS MD. Peptide Receptor Radiotherapy Re-Treatment in Neuroendocrine Tumors: a Systematic review and meta-analysis

#### Conference Proceedings

1. Lesley Anderson, **Michael O'Rorke**, R Wilson, J Jamison, Anna Gavin. HPV prevalence in screened population and types associated with cervix disease in Northern Ireland. 2013. UK's National Cancer Research Institute 2013 Meeting.
2. Emma Herbach, Kristin Weeks, Elizabeth Jasper, **Michael O'Rorke**, Nicole Novak, Marin Schweizer. Disparities in Breast Cancer Mortality Between Immigrant and Native-Born Women: A Meta-Analysis. CUGH 2021 Virtual Conference. 2021

#### Other Publications

1. **Michael O'Rorke**. Review of Gordis Epidemiology, 6th Edition. Doody's Review Service (on-line). Available: <http://www.doody.com/drs/>. (Accessed March 5 2019).

2. **Michael O'Rorke.** Review of Population Biobank Studies: A Practical Guide. Doody's Review Service (online). Available: <http://www.doody.com/drs/>. (Accessed June 4 2021).

## Research Interests/Current Projects

- Cancer Epidemiology
- Neuroendocrine tumors
- Cancer molecular epidemiology
- Pharmacoepidemiology
- Rare Cancer
- Pancreatic Cancer
- Breast Cancer

## Grants and Contracts

### Active (Funded)

1. Neuroendocrine Tumors- Patient Reported Outcomes (NET-PRO); PCORI; O'Rorke, Michael (Principal Investigator)
  - RD-2020C2-20329
  - Jul 1, 2021 - Jul 30, 2024
  - Amount: \$5,113,969.00, Direct Cost: \$1,388,423.00, 35% effort
  - Total Amount Requested: \$5,113,969.00
2. Leveraging SEER-RTR for Difficult to Obtain Specimens; NIH; O'Rorke, Michael (Principal Investigator)
  - 1250124
  - Jul 13, 2023 - Sep 30, 2025
  - Amount: \$119,716.00, Direct Cost: \$76,988.00, 1% effort
3. Supplement, Neuroendocrine Tumors- Patient Reported Outcomes (NET-PRO); PCORI; O'Rorke, Michael (Principal Investigator)
  - RD-2020C2-20329
  - Aug 1, 2024 - Nov 11, 2027
  - Amount: \$499,975.00, Direct Cost: \$368,025.00, 30% effort
4. Neuroendocrine Tumor Specialized Programs of Research Excellent (SPORE) in Human Cancer; NCI; Quelle, Dawn (Multi-PI)
  - 1 P50 CA281855-01
  - Aug 28, 2025 - Aug 31, 2030
  - Amount: \$10,713,580.00, Direct Cost: \$1,464,125.00, 15% effort

### Completed

1. Prognostic role of immune-related factors in early-stage triple-negative and HER2 overexpressing breast cancer: a population-based cohort study; American Cancer Society; O'Rorke, Michael (Principal Investigator)
  - RA 3872
  - Feb 1, 2019 - Jan 1, 2021
  - Amount: \$30,000.00, 0% effort
2. A multi-center, de-identified neuroendocrine tumor database; FMRI/CEPS - Oberley award; O'Rorke, Michael (Principal Investigator)
  - Mar 1, 2020 - Feb 28, 2021
  - Amount: \$24,000.00, 0% effort

3. Adjuvant chemotherapy for resected stage II colon cancer-association with mutational profiling and disease-specific survival: a population-based retrospective cohort study; CEPS - Oberley award; O'Rorke, Michael (Principal Investigator)
  - Oct 1, 2020 - Sep 30, 2021
  - Amount: \$24,617.28, 0% effort
4. SUPPLEMENT - Interim Funds. - Neuroendocrine Tumor Specialized Programs of Research Excellence (SPORE) in Human Cancer; NIH; O'Dorisio, Sue (Principal Investigator)
  - CA174521
  - Sep 1, 2021 - Sep 30, 2022
  - Amount: \$1,200,000.00, Direct Cost: \$794,337.00, 7% effort
  - Total Amount Requested: \$1,200,000.00
5. Agricultural Health Study Tumor Tissue Study; Westat, Inc.; O'Rorke, Michael (Principal Investigator)
  - 1236833
  - May 18, 2021 - Sep 22, 2023
  - Amount: \$113,148.00, 0% effort
6. Understanding the role of DNA damage repair in racial disparities of triple-negative breast cancer outcomes; Washington University in St. Louis/NIH; Shao, Jieya (Principal Investigator)
  - 12400700
  - Feb 3, 2022 - Jan 31, 2024
  - Amount: \$67,250.00
7. Sleep disordered breathing as a targeted risk factor in multiple myeloma; American Cancer Society; Tomasson, Michael (Principal Investigator)
  - RSG-20-017-01-CCE
  - Sep 1, 2020 - Aug 31, 2024
  - Amount: \$792,000.00, 5% effort
8. Sleep Disordered Breathing as a Targetable Risk Factor in Multiple Myeloma; NIH; Tomasson, Michael (Principal Investigator)
  - CA244271
  - Sep 1, 2021 - Present
  - Amount: \$703,889.00, Direct Cost: \$459,637.00, 5% effort
  - Total Amount Requested: \$703,889.00

#### Not Funded

1. microRNAs as a biomarker of tumor progression, and interaction with androgen receptor expression in triple-negative breast cancer: a population-based cohort study; 2020 Breast Cancer Alliance Young Investigator Award
  - Amount: \$200,000.00, 10% effort
  - Total Amount Requested: \$200,000.00
2. Function of Nuclear GRB2 in Human Cells; NIH; Houtman Jon (PI)
  - 1 R01 CA277510-01
  - Sep 1, 2022 - Aug 31, 2023
  - Amount: \$2,978,691.00, Direct Cost: \$1,927,955.00, 5% effort
3. Racial Difference of cGAS-STING Signaling in Triple-Negative Breast Cancer and Its Influence on Outcome Disparity and Therapy Response; Washington University School of Medicine, NIH; O'Rorke, Michael (Contact PI)

- L088400-CG
  - Jul 1, 2023 - Jun 30, 2024
  - Amount: \$39,984.00, Direct Cost: \$25,713.00, 1% effort
4. SEER, Medicare, and Genomic Drivers of Rare Real-World Immune Checkpoint Toxicity & Durable Responses in Patients Living with Metastatic RCC; Yale University, NIH; O'Rorke Michael (contact PI)
    - L079800-CG
    - Jul 1, 2023 - Jun 30, 2024
    - Amount: \$80,834.00, Direct Cost: \$51,983.00, 1% effort
  5. Virtual Tissue Repository 2023-02 Infrastructure Contract; NIH; O'Rorke, Michael (Contact PI)
    - HHSN261201800020I
    - Sep 15, 2023 - Sep 14, 2024
    - Amount: \$529,927.00, Direct Cost: \$340,789.00, 4% effort
  6. Administrative Supplements on Long-term Cancer Survivorship: NIH, PI: Burkard, Mark E, Co-I: O'Rorke, Michael A
    - N016900-G
    - Jul 1, 2025 - Mar 31, 2026
    - Amount: \$100,000.00, Direct Cost: \$68,689.00, 5% effort
  7. CVH TRACK; Louisiana Public Health Institute, NIH; O'Rorke, Michael (Co-Investigator)
    - 1244312
    - Jan 1, 2025 - Dec 31, 2026
    - Amount: \$631,876.00, Direct Cost: \$408,981.00, 10% effort
  8. Microbiome and tumor microenvironment contributions to early-onset colorectal carcinoma incidence and survival outcomes; NIH; Bosch, Dustin (Multi-PI)
    - 1256573
    - Jul 1, 2024 - Jul 1, 2029
    - Amount: \$3,345,360.00, 5% effort
  9. The Relationship of Alcohol Consumption to Mortality and Lung Cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; NIH, PI: Philibert, Robert A, Co-I: O'Rorke, Michael A
    - M785800-G
    - Dec 1, 2025 - Nov 30, 2029
    - Amount: \$3,030,407.00, Direct Cost: \$511,974.00, 12% effort
  10. Anonymized prospective database for the etiologic, prognostic, translational and therapeutic research of patients with neuroendocrine tumors (NETs); CTSA Inter-Institutional Pilot Project Award; O'Rorke, Michael (Principal Investigator)
    - 2019 - Present
    - Amount: \$25,000.00, 0% effort
    - Total Amount Requested: \$25,000.00

### Planned

1. A novel breast cancer treatment strategy using radiopharmaceuticals that target CCR2-positive immune cells in the tumor immune microenvironment; DoD; Houtman, Wadas (Co-PI), O'Rorke (Co-I)
  - Jul 1, 2026 - Aug 31, 2029
  - Amount: \$2,500,000.00, 5% effort

2. Emulations of Target Trials to Comprehensively Evaluate Causal Effect of Incretin Agonists on the development of Cancer in Patients with Obesity and Type 2 Diabetes. NIH; PI: Chrischilles, Elizabeth A; Co-I: O'Rorke, Michael A
  - N084600-CG
  - Jul 1, 2026 - Jun 30, 2031
  - Amount: \$963,038.00, 16% effort

### Under Review

1. Microbiome and tumor microenvironment contributions to early-onset colorectal carcinoma and survival outcomes; NIH; PIs: Bosch, Dustin/Eggers, Shoshannah I; Co-I: O'Rorke, Michael A
  - N001000-G
  - Apr 1, 2026 - Mar 31, 2027
  - Amount: \$3,824,775.00, Direct Cost: \$513,038.00, 5% effort
2. Innovative Terahertz Imaging and Artificial Intelligence Platform for Reducing False Negatives in Sentinel Lymph Node Biopsy: A Preclinical Study. DoD; PI: O'Rorke, Michael A
  - N057500-G
  - Oct 1, 2025 - Sep 30, 2028
  - Amount: \$548,956.00, Direct Cost: \$164,714.00, 15% effort

### **Presentations**

#### Keynote/Plenary Address

Aug 2024 O'Rorke, M; Wahmann M. Patient and stakeholder engagement. Presented at GPC Learning Engagement Conference 2024, Kansas City, MO.

#### Invited Lectures

Aug 25, 2012 NSAIDs and brain tumour risk: a nested case control study using data from the CPRD. Presented at 28th International Conference on Pharmacoepidemiology (ISPE), Barcelona, Spain.

Apr 26, 2013 Early-life and perinatal factors and risk of malignant melanoma. Presented at Melanoma focus, Bristol, United Kingdom.  
Media:  
[http://www.ejancer.com/pb/assets/raw/Health%20Advance/journals/ejc/EJCNews\\_March2013.pdf](http://www.ejancer.com/pb/assets/raw/Health%20Advance/journals/ejc/EJCNews_March2013.pdf)

May 17, 2013 Increasing incidence of HPV-related head and neck cancers and association with survival. Presented at Head and neck cancer symposium – National University of Ireland, Galway, Ireland.

Oct 13, 2015 Warfarin therapy and breast, colorectal, lung and prostate cancer survival. Presented at Vanderbilt University Cancer Symposium, Nashville, Tennessee.

Oct 15, 2015 Warfarin therapy and breast, colorectal, lung and prostate cancer survival. Presented at Kaiser Permanente Research Division, San Francisco, California.

Jul 3, 2016 The Pancreatic Cancer Aetiology and Management study (PanCAM study). Presented at Pancreatic Cancer Research Day – CCRCB QUB, Belfast, Northern Ireland.

Jun 29, 2017 The Centre of Excellence on tour. Presented at UKCRC Progress and Pathways – Royal College of Physicians, London, England.

- Nov 2, 2018 Beta-blocker drug use and BAR expression and breast cancer survival. Presented at Human Physiology Seminar Series.
- Sep 24, 2019 O'Rorke, M. Molecular Cancer Epidemiology. Presented at Behavioral and biomedical interface seminar, University of Iowa.
- Nov 2, 2019 O'Rorke, M. miRNAs and breast cancer survival and prognosis. Presented at HCCC Breast Cancer Symposium.
- Dec 6, 2019 O'Rorke, M. Molecular Cancer Epidemiology. Presented at EHSRC/Superfund/Toxicology seminar.
- 2020 O'Rorke, M. A. Molecular Cancer Epidemiology. Presented at Undergraduate biomedical Sciences Seminar, University of Iowa, Iowa city, Iowa, US/Puerto Rico.
- May 18, 2020 O'Rorke, M. A. Multi-center database for Neuroendocrine Tumors. Presented at NET SPORE Virtual Retreat, University of Iowa, Iowa City, Iowa, US/Puerto Rico.
- May 17, 2021 O'Rorke, M. A. Comparative effectiveness research for neuroendocrine tumors (CER-NET). Presented at VIRTUAL NET SPORE RETREAT, University of Iowa, Iowa City, Iowa, US/Puerto Rico.
- Aug 26, 2021 O'Rorke, M. A. My experience with the Early Career Faculty Academy. Presented at Early Career Faculty Academy kick-off, University of Iowa, Iowa City, Iowa, US/Puerto Rico.
- Oct 24, 2022 **O'Rorke, M. A.** Population-based Studies in Molecular Cancer Epidemiology. Presented at Cancer Biology Seminar, University of Iowa, Iowa City, Iowa.
- Jan 11, 2023 O'Rorke, M. A. PanCAM, PanGEN-EU, NET-PRO and Beyond!. Presented at Liam Murray Cancer Epidemiology Symposium, Queen's University Belfast, Belfast, United Kingdom.
- Jan 27, 2023 O'Rorke, M. Population-based Studies in Molecular Cancer Epidemiology. Presented at The Human Toxicology Program Seminar, Environmental Health Sciences Research Center, Iowa City, Iowa.
- Oct 2025 **Michael A. O'Rorke.** on behalf of the NET-PRO Study Investigators. Neuroendocrine Tumor Research: an Overview. Louisiana State University, Baton Rouge, LA.

#### Oral Presentations

- Jan 10, 2014 Beta-adrenergic receptor expression, beta-blocker drug use and breast cancer survival. Presented at Joint QUB, Vanderbilt cancer symposium, Belfast.
- Jun 18, 2014 Warfarin therapy and breast, colorectal, lung and prostate cancer survival. Presented at 5th UKCRC Public Health Centres of Excellence conference, Leeds, England.
- Oct 6, 2015 Warfarin therapy and breast, colorectal, lung and prostate cancer survival. Presented at National Cancer Intelligence Network (NCIN), Belfast, National Cancer Intelligence Network (NCIN), Belfast.

- Oct 6, 2015 HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix. Presented at National Cancer Intelligence Network (NCIN), Belfast, National Cancer Intelligence Network (NCIN), Belfast.
- Nov 3, 2016 Impact of adjuvant radiotherapy on survival in triple-negative breast cancers. Presented at SMDBS annual Postdoc Soc symposium - QUB, Belfast.
- Jun 16, 2021 O'Rorke, M. A. & O'Rorke, M. A. Comparative Effectiveness Research for Neuroendocrine Tumors (CER-NET). Presented at Holden Comprehensive Cancer center Virtual Scientific Research Retreat, University of Iowa, Iowa City, Iowa, US/Puerto Rico.
- Jun 15, 2022 **O'Rorke, M. A.** Identifying Patient Requirements for Personal Health Record (PHR) Software. Presented at Holden Comprehensive Cancer Centre Annual Retreat, HCCC, io, Iowa.  
Won a prize for best poster
- Oct 4, 2023 O'Rorke, M. [Accessing Big Data; How to answer questions using big data sets.](#) Presented at North American Neuroendocrine Tumor Society (NANETS) 2023, NANETS, Montreal, Canada.
- Apr 2024 O'Rorke, M. Using clinical databases to advance knowledge of NETs. Presented at NCAN 2024 Iowa NET Patient Conference, Hyatt Regency Coralville, IA
- Apr 2024 O'Rorke, M. Neuroendocrine Tumors – Patient Reported Outcomes (NET-PRO): a National Prospective Cohort Study using PCORnet. Presented at 2024 HEALING NET SUMMIT, Hotel Valencia, San Antonio, TX.
- Oct 2025 **Michael A. O'Rorke.** on behalf of the NET-PRO Study Investigators. Designing PCORnet Studies Part 1 - NET-PRO, BEST-ICU - Case studies. Presented at GPC Learning Engagement Conference 2025, Kansas City, MO.
- Oct 2025 **Michael A. O'Rorke,** Tao Xu, Rhonda R. DeCook, Bradley D. McDowell, Brian M. Gryzlak, Nicholas J. Rudzianski, Kimberly C. Serrano, Abigayle M. Wehrheim, Udhayvir S. Grewal, Chandrikha Chandrasekharan, Joseph S. Dillon, Thorvardur R. Halfdanarson, T. Clark Gamblin, Lindsay G. Cowell, Tobias Else, Heloisa P. Soares, Vineeth Sukrithan, Sravani Chandaka, Hanna K. Sanoff, Fiona C. He, David A Geller, Robert A. Ramirez, Mei Liu, William Lancaster, Josh A. Mailman, Heather Moran, Maryann Wahmann, Elyse Gellerman, Elizabeth A. Chrischilles, on behalf of the NET-PRO Study Investigators. Quality of Life and Care Experiences in a U.S. Multi-Institutional Neuroendocrine Tumor Cohort. 2025 NANETS Multidisciplinary NET Medical Symposium. Austin, TX, USA.

## Posters

- Nov 5, 2015 HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix. Presented at All-Ireland Cancer Conference (AICC), Belfast.
- Nov 12, 2015 Impact of adjuvant radiotherapy on survival in triple-negative breast cancers. Presented at San Antonio breast cancer symposium, San Antonio, Texas.
- Nov 18, 2015 Impact of adjuvant radiotherapy on survival in triple-negative breast cancers. Presented at 6th UKCRC Public Health Centres of Excellence National conference, Edinburgh, Scotland.
- Dec 9, 2017 Impact of adjuvant radiotherapy on survival in triple-negative breast cancers. Presented at Queen's Postdoctoral Showcase Event - QUB, Belfast.

- Jun 14, 2023 O'Rorke, M. Self-Reported Treatment & Sequencing in Neuroendocrine Tumors. What's most used, and when?: A National Prospective Cohort Study. Presented at HCCC Annual Retreat 2023, University of Iowa, Iowa City, Iowa.  
Won Top-prize from the Iowa Cancer Consortium for Integration of the Iowa Cancer Plan
- Jun 2024 **O'Rorke Michael A**, DeCook Rhonda R, McDowell Bradley D, Gryzlak Brian M, Rudzianski Nicholas J, Chandrasekharan Chandrikha, Dillon Joseph, Chrischilles Elizabeth A. On behalf of the NET-PRO study Investigators. Neuroendocrine Tumors – Patient Reported Outcomes (NET-PRO) : Self-Reported Outcomes & changes in HRQoL. Presented at HCCC Annual Symposium. Won Best Poster prize for Iowa Cancer Consortium Cancer Plan Integration
- Jun 2025 **Michael A. O'Rorke**, Tao Xu, Rhonda R. DeCook, Bradley D. McDowell, Brian M. Gryzlak, Nicholas J. Rudzianski, Kimberly C. Serrano, BA, Abigayle M. Wehrheim, Udhayvir S. Grewal, Chandrikha Chandrasekharan, Joseph S. Dillon, Elizabeth A. Chrischilles, on behalf of the NET-PRO Study Investigators. Quality of Life and Care Experiences in a U.S. Multi-Institutional Neuroendocrine Tumor Cohort: Baseline Results from the NET-PRO Study. HCCC Symposium 2025. Coralville, IA

### Panels

- May 14, 2021 O'Rorke, M. Comparative Effectiveness Research for Neuroendocrine Tumors (CER-NET). Presented at Rare Disease Advisory Panel, Patient-Centered Outcomes Research Institute (PCORI), Iowa City, Iowa, US/Puerto Rico.
- Jun 7, 2022 **O'Rorke, M. A.** NET-PRO Study Progress. Presented at PCORnet Phase 3 Steering Committee, University of Iowa, Washington DC, Maryland.
- Jul 18, 2023 O'Rorke, M. NET-PRO Project Progress Update. Presented at PCORnet Phase 3 Steering Committee, PCORnet.
- Jul 2024 **O'Rorke, M.** NET-PRO Project Progress Update. Presented at PCORnet Phase 3 Steering Committee, PCORnet
- Jul 2025 **O'Rorke, M.** NET-PRO Project Progress Update. Presented at PCORnet Phase 3 Steering Committee, PCORnet

### Seminars

- Apr 27, 2022 **O'Rorke, M. A.** Neuroendocrine Tumors – Patient Reported Outcomes (NET-PRO). Presented at Cancer Epidemiology Seminar, Queen's University Belfast, Belfast, United Kingdom.
- Oct 26, 2023 O'Rorke, M. Accessing Big Data for Rare Disease Research. Neuroendocrine Tumors – Patient Reported Outcomes (NET-PRO): a National Prospective Cohort Study using PCORnet. Presented at Stakeholders, Technology and Research CRN (STAR) Quarterly update, Stakeholders, Technology and Research CRN (STAR).

Dec 1, 2023 O'Rorke, M., Brian, G., McDowell, B. & Hourcade, J. Rare disease research in PCORnet: Lessons learned from the Neuroendocrine – Patient Reported Outcomes (NET-PRO) project. Presented at PCORnet Best Practice Sharing Session, PCORnet. Achieving progress against rare cancers requires that large-scale clinical research networks be employed for cancer research. In this session we will share highlights and lessons learned from the conduct of the NET-PRO study: a National Prospective Cohort Study using PCORnet. Elements of the presentation will include an overview of the design and implementation of a computable phenotype(s) to identify a rare disease, and lessons learned from direct engagement from rare disease patients (focus groups and usability testing of a patient portal for on-line consent and enrollment and administration of follow-up surveys) and insight on the management of a multi-site cohort study including REDCap and SharePoint infrastructure.

Other Presentations

Oct 19, 2018 Molecular Epidemiology of Cancer. Presented at HCCC Grand Rounds.

Service

**Professional Service**

Professional Organizations

2022 - Present Population Sciences Working Group, American Association for Cancer Research (AACR)

Journal Reviews/Referee Manuscripts

2011 - Present BMC Cancer, Reviewer  
 2011 - Present Br J Cancer, Reviewer  
 2011 - Present Cancers and Biosci Rep, Reviewer  
 2011 - Present Clin Microbiol Infec, Reviewer  
 2011 - Present Int J Cancer, Reviewer  
 2011 - Present JAMA, Reviewer  
 2011 - Present Sci Total Environ, Reviewer  
 2011 - Present World J Gastroenterol, Reviewer  
 2011 - Present World Journal of Meta-Analysis, Reviewer  
 2011 - Present Am J Clin Nut, Reviewer  
 2024 - Present Springer Nature, Reviewer  
 2024 - Present Cancer Causes Control, Reviewer

Review Panels

2020 2020 Breast Cancer Research Program (BCRP), Congressionally Directed Medical Research Programs (CDMRP), Reviewer, Grant Proposals

### Organize Conferences, Sessions, etc.

- 2012 International Nutrition Society Conference
- 2017 UKCRC Public Health Research Centres of Excellence 2017 Conference (Royal College of Physicians, London)

### Professionally Relevant Community Involvement

- 2014 Cancer research advancing patient care
- 2014 CRUK all-party working group – early diagnosis of cancer, Stormont Executive (policy engagement)
- 2014 - 2015 Queen's University Human Tissue Act (HTA) audits (PanCAM study and CRUK fellowship study)
- 2014 - 2017 Culture Night Belfast
- 2014 - 2017 Northern Ireland Science Festival
- 2017 QUB research showcase event
- 2017 Science Uncovered
- 2014 - 2018 STEMNET Ambassador
- 2015 - 2018 Centre for Cancer Research & Cell Biology open day
- 2016 - 2018 Northern Ireland Science Festival
- 2017 - 2018 Antibiotic Awareness – EBUGS (<http://www.e-bug.eu/>)

### Other

- 2014 - 2018 World Journal of Meta-Analysis (WJMA), Editorial Board

## **University, College, Department Service**

### University

- 2011 - 2012 Student representative for the PGCHET Staff Student Consultative Committee, Queens University Belfast, Member
- 2012 - 2014 School of Medicine, Dentistry and Biomedical Sciences Postdoctoral Society, Queens University Belfast, Chair
- 2011 - 2016 Primary Care Research Group journal club (School of Pharmacy), Queens University Belfast, Member
- 2007 - 2017 Cancer Epidemiology & Health Services Research Group Journal Club, Queens University Belfast, Member
- Sep 1, 2019 - Aug 1, 2022 HCCC Scientific Research Retreat Committee, Member
- Sep 1, 2021 - Aug 1, 2023 Faculty ICON Steering Committee, Iowa City, Iowa, US/Puerto Rico, Member
- Aug 4, 2021 - Aug 31, 2024 Medical Science Training Program (MSTP) Admissions Committee, Iowa City, Iowa, Member
- Aug 1, 2022 - Present CEPS Leadership Committee, Iowa City, Iowa, Member

Aug 21, 2023 - Present American Cancer Society-Institutional Research Grant (ACS-IRG) - Institutional Research Review Committee, Member  
2025 - Present Medical Science Training Program (MSTP) Admissions Committee, Iowa City, Iowa, Member

### College

Sep 1, 2020 - May 31, 2023 Research Council CPH, Member

Sep 1, 2023 - Present MPH Implementation Team departmental subgroup, Iowa City, Iowa, Member

### Department

Oct 19, 2023 - Jul 31, 2024 Epi Faculty Search Committee, Iowa City, Iowa, Member

Aug 20, 2018 - Present MPH Admissions Review, Committee Assignment

Aug 20, 2018 - Present PHD Admissions Review, Committee Assignment

Aug 23, 2021 - Present MS EXAM, Member